Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Growth Story

This article was originally published in The Pink Sheet Daily

Executive Summary

A message to the market: We're big and getting bigger

You may also be interested in...



With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations

While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.

With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations

While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.

Teva Swoops In To Snatch Cephalon For $6.7 Billion

Cephalon, the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International, the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel